ENZN Enzon Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. OTC: ENZN

Price (delayed)

$0.2103

Market cap

$15.61M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.02

Enterprise value

-$31.37M

Highlights
Enzon Pharmaceuticals's net income has surged by 75% QoQ and by 60% YoY
The company's EPS has surged by 50% QoQ and by 33% YoY
The equity has contracted by 30% YoY but it has grown by 24% from the previous quarter
ENZN's revenue has dropped by 96% year-on-year and by 10% since the previous quarter
The gross profit has plunged by 96% YoY and by 10% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://enzon.com/
Peers: NKTR AMGN ENTA BMY

Key stats

What are the main financial stats of ENZN
Market
Shares outstanding
74.21M
Market cap
$15.61M
Enterprise value
-$31.37M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.58
Price to sales (P/S)
600.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-1,206.72
Earnings
Revenue
$26,000
EBIT
-$386,000
EBITDA
-$386,000
Free cash flow
-$659,000
Per share
EPS
-$0.02
Free cash flow per share
-$0.01
Book value per share
$0.05
Revenue per share
$0
TBVPS
$0.64
Balance sheet
Total assets
$47.59M
Total liabilities
$44.18M
Debt
$0
Equity
$3.41M
Working capital
$45.69M
Liquidity
Debt to equity
0
Current ratio
27.89
Quick ratio
27.65
Net debt/EBITDA
121.72
Margins
EBITDA margin
-1,484.6%
Gross margin
100%
Net margin
-715.4%
Operating margin
-3,969.2%
Efficiency
Return on assets
-3.1%
Return on equity
-43.3%
Return on invested capital
N/A
Return on capital employed
-0.8%
Return on sales
-1,484.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ENZN stock price

How has the Enzon Pharmaceuticals stock price performed over time
Intraday
-12.01%
1 week
-17.01%
1 month
-22.11%
1 year
-29.9%
YTD
-14.75%
QTD
-14.75%

Financial performance

How have Enzon Pharmaceuticals's revenue and profit performed over time
Revenue
$26,000
Gross profit
$26,000
Operating income
-$1.03M
Net income
-$186,000
Gross margin
100%
Net margin
-715.4%
The operating income has plunged by 120% YoY but it has soared by 58% from the previous quarter
ENZN's revenue has dropped by 96% year-on-year and by 10% since the previous quarter
The gross profit has plunged by 96% YoY and by 10% from the previous quarter
Enzon Pharmaceuticals's net income has surged by 75% QoQ and by 60% YoY

Growth

What is Enzon Pharmaceuticals's growth rate over time

Valuation

What is Enzon Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.58
P/S
600.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-1,206.72
The company's EPS has surged by 50% QoQ and by 33% YoY
The stock's price to book (P/B) is 35% more than its 5-year quarterly average of 3.4 but 28% less than its last 4 quarters average of 6.4
The equity has contracted by 30% YoY but it has grown by 24% from the previous quarter
ENZN's revenue has dropped by 96% year-on-year and by 10% since the previous quarter
The P/S is 5% above the last 4 quarters average of 570.0

Efficiency

How efficient is Enzon Pharmaceuticals business performance
ENZN's return on assets is up by 48% since the previous quarter and by 40% year-on-year
Enzon Pharmaceuticals's return on equity has increased by 43% QoQ but it has decreased by 2.9% YoY
The company's return on sales rose by 43% QoQ

Dividends

What is ENZN's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Recent dividends

Financial health

How did Enzon Pharmaceuticals financials performed over time
Enzon Pharmaceuticals's total assets is 8% more than its total liabilities
ENZN's quick ratio has dropped by 77% year-on-year and by 75% since the previous quarter
The current ratio has plunged by 76% YoY and by 75% from the previous quarter
ENZN's debt is 100% smaller than its equity
The equity has contracted by 30% YoY but it has grown by 24% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.